Pfizer China Launches Ecnoglutide – World’s First cAMP-Biased GLP-1 Drug
Jun 01,2026
On May 31, 2026,Pfizer China has launched Xianweiyin® (Ecnoglutide Injection) , the world’s first cAMP-biased GLP-1 receptor agonist, approved in China for type 2 diabetes and chronic weight management.
Phase III SLIMMER trial (48 weeks, n=664, overweight/obesity):
- 15.4% mean weight loss at 2.4 mg
- 92.8% achieved ≥5% weight loss
- GI-related discontinuation rate: only 0.6% – significantly lower than traditional GLP-1 drugs (>1%)
- Mean waist circumference reduction: 12.8 cm
- No traditional weight-loss plateau observed
Mechanism advantage:
Based on Nobel Prize-winning GPCR research, Ecnoglutide preferentially activates metabolic pathways for weight loss and glucose control while reducing gastrointestinal side effects.
Origin & pipeline:
Discovered by Sciwind Biosciences (Hangzhou). Pfizer holds exclusive commercial rights in mainland China in a deal valued up to $495 million. An oral formulation is also in global development.
Remark: This content is AI-generated and for reference only. It is compiled from online sources. Please refer to official information for accuracy.
Syntame Exhibition Tour 2025
CPHI South East Asia 2025 comes to a successful conclusion | SYNTAME opens a new chapter in the Southeast Asian market
CPHI China 2025 ended successfully | Syntame talks with customers around the world about new opportunities for cooperation
The company team made a stunning appearance at the 22nd World Pharmaceutical Raw Materials China Exhibition (CPHI) at the Shanghai New International Expo Centre.
The company's sales team successfully participated in the 21st World Pharmaceutical Raw Materials China Exhibition (CPHI) at the Shanghai New International Expo Centre.
No.298 Mingguang Road, Urban Industrial Park, Yinzhou District, Ningbo City, Zhejiang Province, P.R. China
